 Aeglea BioTherapeutics, Inc. AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced that, due to the public health impact of the coronavirus COVID-19 pandemic, the location of the Companys 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only. To be admitted to the annual meeting at stockholders must enter the control number found on their proxy card, voting instruction form or notice previously received. Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. 